A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FAZIRSIRAN IN THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY-ASSOCIATED LIVER DISEASE WITH METAVIR STAGE F1 FIBROSIS

Registry ID

TAK-999-3002

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

TAKEDA DEVELOPMENT CENTER AMERICAS INC

Start date

2024-04-26

Last update

2024-01-23

Conditions

• LIVER DISEASE

Related clinical trials

• A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GSK4532990 FOR STEATOHEPATITIS IN ADULTS WITH ALCOHOL RELATED LIVER DISEASE (ALD)
• EFFECTS OF NNC0194-0499 ALONE AND IN COMBINATION WITH SEMAGLUTIDE, OF SEMAGLUTIDE ALONE, AND OF CAGRILINTIDE ALONE AND IN COMBINATION WITH SEMAGLUTIDE ON LIVER DAMAGE AND ALCOHOL USE IN PEOPLE WITH ALCOHOL-RELATED LIVER DISEASE

View on source registry